Leadership in Digital Health and Artificial Intelligence

Professor Pascale Guitera serves in several strategic positions that advance the integration of artificial intelligence in dermatology. As a member of the e-Health committee of the Australasian College of Dermatology since May 2020, who has contributed to multiple publications and recently assisted the Therapeutic Goods Administration in defining labeling requirements for AI applications in dermatology. She coordinates international challenges through the International Skin Imaging Collaboration (ISIC). She serves on the dermatology advisory board, as well as participates in the task force for EADV, where she develops guidelines and educational frameworks.

​

Her research portfolio includes several major clinical initiatives. She serves as the principal or co-investigator on multiple large-scale studies, including a randomized controlled trial examining patient-led melanoma surveillance (valued at $1.2M over 4 years) and a pioneering study testing AI-assisted diagnosis in general practice settings with plans for a comprehensive implementation study in remote and rural communities integrating risk assessment, AI tools, and healthcare pathways.

She is leading international collaborative efforts to advance AI from dermoscopy images to clinical and mobile phone imaging, working with research centers across multiple continents. This includes ACEMID, an infrastructure grant (10M) from ACRF as CI for the Australian Center of Excellence in Melanoma Imaging & Diagnosis, which won the Australian Museum Eureka Prize 2024, and the USA Department of Defense-funded work on 3D total body photography. She is also working on AI development for confocal microscopy diagnosis and line field confocal optical coherence tomography. 

​

​

Lentigo Maligna Research

As Chief Investigator, Professor Pascale Guitera led a multicenter Phase III randomized controlled trial comparing imiquimod topical treatment versus radiotherapy for lentigo maligna, recruiting 126 patients at 8 international centres. Despite covid challenges, the study has produced one published paper and three additional manuscripts in development covering health economics, quality of life outcomes, and confocal microscopy follow-up. This work contributed to changing national and international clinical guidelines, collaborating with leading institutions to update management recommendations.

​

​

Advanced Imaging and Diagnostic Innovation

Professor Pascale Guitera is Chief Investigator on "Cancer UNCUT," a $2.7M prospective double-blind randomized controlled trial examining the clinical and cost-effectiveness of adjunctive in vivo reflectance confocal microscopy for skin cancer diagnosis across 12 sites. Additionally, she is pioneering research in tumor microenvironment visualization and morphology biology, seeking to understand mechanisms of early-stage melanocytic lesions and treatment sensitivities.